A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance

Abstract Background: Research on cannabis‐based medicinal products (CBMPs) in anxiety remains inconclusive due to a paucity of high‐quality evidence. Studies indicate a bidirectional relationship between generalized anxiety disorder (GAD) and sleep disruption, but it is unclear how this affects CBMP treatment outcomes. This study aims to compare the patient‐reported outcome measures (PROMs) of patients prescribed CBMPs for GAD, with and without impaired sleep. Methods: Changes in PROMs were recorded from baseline to 1, 3, 6, and 12 months between those